Kynexis raised €57 Million Series A Financing to advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
CEO of Kynexi
Working with 2 Bridge and accessing their pool of expertise and resources allowed us to become fully operational in a short period of time. As a result, we were able to generate momentum that was important for meeting an important regulatory milestone and raising our recent €57 million Series A round. The Series A will enable us to advance our lead candidate, KYN-5356, to Phase 2 clinical trial completion.
Peter Høngaard Anderse
Operating Partner at Forbion & Executive Chairman of Kynexis
Starting a company from scratch is challenging and by bringing 2 Bridge inside, we were able to quickly get going with a team that brought all the relevant expertise to the table in drug development, such as regulatory affairs, clinical trial design and operations and CMC.